tbuckley/cabot-search huggingface dataset:
Educating Cardiovascular Fellows in the Contemporary Era
Authors: Rick A. Nishimura, Carole A. Warnes
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
National Institute of Environmental Health Sciences: 50 Years of Advancing Science and Improving Lung Health
Authors: Veena B. Antony, Carrie A. Redlich, Kent E. Pinkerton, John Balmes, Jack R. Harkema
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

The American Thoracic Society celebrates the 50th anniversary of the National Institute of Environmental Health Sciences (NIEHS). The NIEHS has had enormous impact through its focus on research, training, and translational science on lung health. It has been an advocate for clean air both in the United States and across the world. The cutting-edge science funded by the NIEHS has led to major discoveries that have broadened our understanding of the pathogenesis and treatment for lung disease. Importantly, the NIEHS has developed and fostered mechanisms that require cross-cutting science across the spectrum of areas of inquiry, bringing together environmental and social scientists with clinicians to bring their expertise on specific areas of investigation. The intramural program of the NIEHS nurtures cutting-edge science, and the extramural program encourages investigator-initiated research while at the same time providing broader direction through important initiatives. Under the umbrella of the NIEHS and guided by Dr. Linda Birnbaum, the director of the NIEHS, important collaborative programs, such as the Superfund Program and the National Toxicology Program, work to discover mechanisms to protect from environmental toxins. The American Thoracic Society has overlapping goals with the NIEHS, and the strategic plans of both august bodies converge to synergize on population lung health. These bonds must be tightened and highlighted as we work toward our common goals.
Chemical Enhancement of In Vitro and In Vivo Direct Cardiac Reprogramming
Authors: Tamer M. A. Mohamed, Nicole R. Stone, Emily C. Berry, Ethan Radzinsky, Yu Huang, Karishma Pratt, Yen-Sin Ang, Pengzhi Yu, Haixia Wang, Shibing Tang, Sergey Magnitsky, Sheng Ding, Kathryn N. Ivey, Deepak Srivastava
Journal: Circulation (2016)

Reprogramming of cardiac fibroblasts into induced cardiomyocyte-like cells in situ represents a promising strategy for cardiac regeneration. A combination of 3 cardiac transcription factors, Gata4, Mef2c, and Tbx5 (GMT), can convert fibroblasts into induced cardiomyocyte-like cells, albeit with low efficiency in vitro.We screened 5500 compounds in primary cardiac fibroblasts to identify the pathways that can be modulated to enhance cardiomyocyte reprogramming.We found that a combination of the transforming growth factor-β inhibitor SB431542 and the WNT inhibitor XAV939 increased reprogramming efficiency 8-fold when added to GMT-overexpressing cardiac fibroblasts. The small molecules also enhanced the speed and quality of cell conversion; we observed beating cells as early as 1 week after reprogramming compared with 6 to 8 weeks with GMT alone. In vivo, mice exposed to GMT, SB431542, and XAV939 for 2 weeks after myocardial infarction showed significantly improved reprogramming and cardiac function compared with those exposed to only GMT. Human cardiac reprogramming was similarly enhanced on transforming growth factor-β and WNT inhibition and was achieved most efficiently with GMT plus myocardin.Transforming growth factor-β and WNT inhibitors jointly enhance GMT-induced direct cardiac reprogramming from cardiac fibroblasts in vitro and in vivo and provide a more robust platform for cardiac regeneration.
Definition of a Diagnostic Window Prior to the Onset of Clinically Apparent Acute Graft-Versus-Host Disease.
Authors: Carina A Bäuerlein, Simone S Riedel, Brede Christian, Ana-Laura Jordán Garrote, Agnes Birner, Carolin Kiesel, Miriam Ritz, Stephan Schulz, Marina Grether, Georg F Beilhack, Robert Negrin, Hermann Einsele, Andreas Beilhack
Journal: Blood (2010)
A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus
Authors: Florence Magrangeas, Rowan Kuiper, Hervé Avet-loiseau, Wilfried Gouraud, Catherine Guérin, Henri Der Sakissian, Jérôme Suhard, Michel Attal, Pieter Sonneveld, Charles Dumontet, Philippe Moreau, Mark van Duin, Loic Campion, Stephane Minvielle
Journal: Blood (2014)
Serum cathelicidin, nasopharyngeal microbiota, and disease severity among infants hospitalized with bronchiolitis
Authors: Kohei Hasegawa, Jonathan M. Mansbach, Nadim J. Ajami, Joseph F. Petrosino, Robert J. Freishtat, Stephen J. Teach, Pedro A. Piedra, Carlos A. Camargo
Journal: Journal of Allergy and Clinical Immunology (2016)
Azacytidine (AZA) In Relapsed MDS and AML After Allogeneic Stem Cell Transplantation (allo-HSCT): Results of the French ATU Program.
Authors: Romain Guièze, Anne Jouinot, Raphael Itzykson, Sylvain Thepot, Thierry Guillaume, Valérie Coiteux, Sébastien Wittnebel, Stéphane de Botton, Caroline Dartigeas, Anne Sirvent, Pascal Turlure, Didier Bouscary, Marie Robin, Jean-Paul Vernant, Laurent Sutton, Francois Dreyfus, Jacques-Olivier Bay, Lionel Ades, Pierre Fenaux
Journal: Blood (2010)
AB0763 Does Decreased Bone Mineral Density Affect Clinical Manifestation in Knee Osteoarthritis Women?
Authors: T. Tarasenko, N. Shuba
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Current studies and research support the role of bone mineral density (BMD) in knee osteoarthritis (KOA). However, few studies have focused on its impact on KOA parameters. <h3>Objectives</h3> The aim of this study was to investigate if decrease of BMD affect the intensity of pain, functional disability, and radiographic severity in KOA women. <h3>Methods</h3> We conducted a cross sectional study including confirmed radiographic knee osteoarthritis according to Kellgren and Lawrence scale, with normal and reduced BMD according to the classification of Report of a WHO Study Group. The two groups were compared on pain Visual Analogue Scale (VAS), Lequesne index, Womac function, and radiological grade after adjusting for significant covariates. Multiple regression analysis was used to identify the independent effects of each specific component for decrease of BMD on knee osteoarthritis parameters. <h3>Results</h3> One hundred forty women were included. The mean age was 55,28±8,08 [37–75] years, and the mean BMI was 30,18±2,43 [23–37] kg/m<sup>2</sup>. The prevalence of decrease of bone mineral density was 55,7%. Women with and without osteoporosis had similar KOA parameters. Multiple regression analyses showed, after adjusting for all covariates, that decrease of BMD had a positive impact on pain VAS (p=0,002) and WOMAC (p=0,003), an indicator of restrictions on daily activity WOMAC (p=0,08), Lequesne index (p=0,001). Noted that lower parameters BMD was significantly associated with high level of CRP (p=0,04). <h3>Conclusions</h3> In patients KOA with a concomitant decrease in BMD revealed a distinct pain in the knee by VAS and index WOMAC, a strong indicator of restrictions on daily activity WOMAC, more high Lekena index and a higher level of CRP. <h3>References</h3> In addition to anti-inflammatory therapy, appropriate treatment of osteoporosis needs to become an important management strategy for knee pain and functional impairment. <h3>Disclosure of Interest</h3> None declared
Cladribine in Combination with Standard Daunorubicine and Cytarabine (DAC) as a Remission Induction Treatment Improves the Overall Survival in Untreated Adults with AML Aged &lt; 60 y Contrary to Combination Including Fludarabine (DAF): A Multicenter, Randomized, Phase III PALG AML 1/2004 DAC/DAF/DA Study in 673 Patients-A Final Update.
Authors: Jerzy Holowiecki, Sebastian Grosicki, Slawomira Kyrcz-Krzemien, Kazimierz Kuliczkowski, Aleksander B Skotnicki, Andrzej Hellmann, Tadeusz Robak, Kazimierz Sulek, Anna Dmoszynska, Janusz Kloczko, Wieslaw Wiktor Jedrzejczak, Barbara Zdziarska, Krzysztof Warzocha, Krystyna Maria Zawilska, Sebastian Giebel, Mieczyslaw Komarnicki, Marek Kielbinski, Beata Piatkowska-Jakubas, Agnieszka Wierzbowska, Olga Haus, Beata Stella-Holowiecka, Malgorzata Krawczyk-Kulis, Malgorzata Wach, Tomasz Czerw, Anna Ejduk
Journal: Blood (2009)
Disaggregating asthma: Big investigation versus big data
Authors: Danielle Belgrave, John Henderson, Angela Simpson, Iain Buchan, Christopher Bishop, Adnan Custovic
Journal: Journal of Allergy and Clinical Immunology (2016)

We are facing a major challenge in bridging the gap between identifying subtypes of asthma to understand causal mechanisms and translating this knowledge into personalized prevention and management strategies. In recent years, "big data" has been sold as a panacea for generating hypotheses and driving new frontiers of health care; the idea that the data must and will speak for themselves is fast becoming a new dogma. One of the dangers of ready accessibility of health care data and computational tools for data analysis is that the process of data mining can become uncoupled from the scientific process of clinical interpretation, understanding the provenance of the data, and external validation. Although advances in computational methods can be valuable for using unexpected structure in data to generate hypotheses, there remains a need for testing hypotheses and interpreting results with scientific rigor. We argue for combining data- and hypothesis-driven methods in a careful synergy, and the importance of carefully characterized birth and patient cohorts with genetic, phenotypic, biological, and molecular data in this process cannot be overemphasized. The main challenge on the road ahead is to harness bigger health care data in ways that produce meaningful clinical interpretation and to translate this into better diagnoses and properly personalized prevention and treatment plans. There is a pressing need for cross-disciplinary research with an integrative approach to data science, whereby basic scientists, clinicians, data analysts, and epidemiologists work together to understand the heterogeneity of asthma.
Monitoring of 1,3-Beta-D-Glucan (BGL) Antigenemia in Neutropenic Patients with Acute Leukemia at High Risk for Invasive Fungal Infections (IFI).
Authors: Laurence Senn, James O. Robinson, Sabine Schmidt, Marlies Knaup, Nobuo Asahi, Shinji Satomura, Shuuji Matsuura, Jacques Bille, Bertrand Duvoisin, Thierry Calandra, Oscar Marchetti
Journal: Blood (2006)
PWE-152 Faecal Elastase: Impact of Age, Sex, Ethnicity, Pre-Existing Pancreatic Endocrine Dysfunction and Indication for Testing On Faecal Elastase Results
Authors: YK Kim, A Soubieres, A Buckingham, C Woodhouse, I Khan, DC Gaze, F Boa, A Poullis
Journal: Gut (2016)

<h3>Introduction</h3> Pancreatic Exocrine Insufficiency (PEI) is underdiagnosed and faecal elastase (FE) testing underutilised. The impact of age, sex, ethnicity, pre-existing pancreatic endocrine dysfunction and indication for testing on faecal elastase results are poorly studied. Previous small studies have suggested an age related decline in FE levels. Our Institution serves an ethnically mixed population in South London and we have described previously un-know ethnicity differences in colonic polyp prevalence,<sup>1</sup> intestinal metaplasia in Barrett’s oesophagus<sup>2</sup> and vitamin D deficiency in inflammatory bowel disease.<sup>3</sup> <h3>Methods</h3> A retrospective study on 530 patients who underwent FE testing from September 2011 to September 2015 was carried out. Patient demographics were retrieved from hospital records. Ethnicity was categorised as ‘Indian-subcontinent’ and “Non-Indian-subcontinent’ as previously described (1). Paediatric cases (age less than 1) and adults with incomplete data were excluded from analyses. These were performed using Analyse-it Version 2.30 for Microsoft Excel. 494 cases were analysed. <h3>Results</h3> Mean age of study participants was 50.7 (sd 22.7), there were 251 females and 243 males. The mean FE in our population was 381µg/g (sd 166). 89/494 were diagnosed with PEI. There was no significant difference in FE result when analysed for age, sex, ethnicity and history of weight loss. No age related differences were found when analysed for mean age in those with normal v abnormal FE results (20.2 v 52.9, p = n.s.), age v FE level or age v FE level in those with PEI. Patients with pre-existing diabetes mellitus were significantly more likely to have PEI (DM v no DM: FE low in 28 v 16%, p = 0.03). Patients presenting with unexplained diarrhoea were significantly more likely to have PEI (diarrhoea v no diarrhoea: FE low in 20.5 v 10.6, p = 0.009). <h3>Conclusion</h3> This is the first study investigating the effects ethnicity and indication for testing on FE result and the largest study looking at the effect of age. Contrary to earlier smaller studies we found no relationship to age. We identified that patients with diarrhoea rather than isolated weight loss have a higher detection rate for PEI. We confirmed previous observations that patients with diabetes have a higher rate of PEI. FE testing should routinely be carried out in patients with unexplained diarrhoea. <h3>References</h3> 1 West NJ, Poullis A. <i>Indian J Gastroenterol</i> 2007. 2 Hewett R, Poullis A. <i>Indian J Gastroenterol</i> 2015. 3 Chatu S, Poullis A. <i>Frontline Gastroenterol</i> 2013. <h3>Disclosure of Interest</h3> None Declared
Malignant Myeloma Cells Impair Phenotype and Function of stem and Progenitor Cells.
Authors: Ingmar Bruns, Sebastian Büst, Akos G. Czibere, Ron-Patrick Cadeddu, Ines Brückmann, Manoj Bhasin, Johannes C Fischer, Roland Fenk, Guido Kobbe, Andreas Trumpp, Rainer Haas
Journal: Blood (2009)
CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells.
Authors: Rena J. May, Javier Pinilla, Tatyana Korontsvit, Victoriya Zakhaleva, Ronghua H. Zhang, Tao Dao, Peter Maslak, David A. Scheinberg
Journal: Blood (2006)
A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm
Authors: Michele Ceribelli, Zhiying Esther Hou, Priscilla N. Kelly, Da Wei Huang, George Wright, Karthik Ganapathi, Moses O. Evbuomwan, Stefania Pittaluga, Arthur L. Shaffer, Guido Marcucci, Stephen J. Forman, Wenming Xiao, Rajarshi Guha, Xiaohu Zhang, Marc Ferrer, Laurence Chaperot, Joel Plumas, Elaine S. Jaffe, Craig J. Thomas, Boris Reizis, Louis M. Staudt
Journal: Cancer Cell (2016)
Efficacy of Caspofungin as Secondary Prophylaxis in Patients Undergoing Stem Cell Transplantation with Prior Pulmonary and/or Systemic Fungal Infection.
Authors: Paolo de Fabritiis, Laura Cudillo, Paolo Di Bartolomeo, Anna Locasciulli, Giuseppe Milone, Stefania Fallani, Alessandro Busca, Rosanna Scimè, Simona Sica, Alessandra Spagnoli, Stella Santarone, Ignazio Majolino, Massimo Poidomani, Andrea Novelli
Journal: Blood (2005)
THU0322 Altered Quality of Life Is Mainly Associated with Patient Reported Outcomes in Primary Sjögren's Syndrome Patients: Data from A Large Therapeutic Trial: Table 1.
Authors: D. Cornec, V. Devauchelle-Pensec, X. Mariette, S. Jousse-Joulin, J.-M. Berthelot, A. Perdriger, X. Puéchal, V. Le Guern, J. Sibilia, J.-E. Gottenberg, L. Chiche, E. Hachulla, P.-Y. Hatron, V. Goeb, G. Hayem, J. Morel, C. Zarnitsky, J.J. Dubost, P. Saliou, J.O. Pers, R. Seror, A. Saraux
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> To identify the main determinants of quality of life (QoL) alteration in patients with active primary Sjögren9s syndrome (pSS) participating in a large therapeutic trial. <h3>Methods</h3> At the inclusion visit in the TEARS trial, 120 patients with active pSS completed the Short Form survey 36 (SF36), a validated tool measuring the level of QoL. The association of demographic data, patient-reported outcomes (including the EULAR SS Patient Reported Index (ESSPRI) score), objective measurements of dryness and autoimmunity, and the physician evaluation of systemic activity (using the EULAR SS Disease Activity Index (ESSDAI) score) with SF36 physical and mental components were assessed by univariate then multivariate linear regression analyses. <h3>Results</h3> SF36 results showed a marked alteration of QoL in this population of patients with active pSS. The strongest predictors of a low QoL (for both physical and mental components, Table 1) were patient-reported symptoms, best assessed using the ESSPRI, with pain and ocular dryness intensity displaying independent association with QoL. Conversely, systemic activity level was not associated to QoL alteration, even in the subset of patients with moderate to high systemic activity as defined by the ESSDAI. <h3>Conclusions</h3> pSS cardinal symptoms (dryness, fatigue and pain) are the major predictors of QoL alteration and should be targeted in future therapeutic trials in addition to systemic involvement. <h3>Disclosure of Interest</h3> None declared
Attending in‐person dermatology teaching meetings: the patients’ experience
Authors: A. Ascott, V.M.L. Jolliffe
Journal: British Journal of Dermatology (2016)

E-learning and telemedicine are increasingly popular in the teaching and diagnosis of dermatology1,2. E-learning can be completed at a learner's own pace, and can be ideal for visual specialties. However, there are certain limitations relevant to dermatology: store-and-forward images provide only a snapshot of the condition, when whole body examination may be indicated. Moreover, information from skin palpation forms a significant part of teaching dermatology. In our experience of delivering an online post-graduate Diploma in dermatology, we have sought to overcome these limitations by hosting 6 clinical teaching meetings annually, comprising in-person small group teaching with ‘live’ patient cases. Feedback from our students confirms that these meetings are very popular, demonstrating the value of ‘live’, patient-centered learning to the postgraduate learner.

This article is protected by copyright. All rights reserved.
Potential biomarkers to follow the progression and treatment response of Huntington’s disease
Authors: Marie-Hélène Disatnik, Amit U. Joshi, Nay L. Saw, Mehrdad Shamloo, Blair R. Leavitt, Xin Qi, Daria Mochly-Rosen
Journal: The Journal of Experimental Medicine (2016)

Huntington’s disease (HD) is a rare genetic disease caused by expanded polyglutamine repeats in the huntingtin protein resulting in selective neuronal loss. Although genetic testing readily identifies those who will be affected, current pharmacological treatments do not prevent or slow down disease progression. A major challenge is the slow clinical progression and the inability to biopsy the affected tissue, the brain, making it difficult to design short and effective proof of concept clinical trials to assess treatment benefit. In this study, we focus on identifying peripheral biomarkers that correlate with the progression of the disease and treatment benefit. We recently developed an inhibitor of pathological mitochondrial fragmentation, P110, to inhibit neurotoxicity in HD. Changes in levels of mitochondrial DNA (mtDNA) and inflammation markers in plasma, a product of DNA oxidation in urine, mutant huntingtin aggregates, and 4-hydroxynonenal adducts in muscle and skin tissues were all noted in HD R6/2 mice relative to wild-type mice. Importantly, P110 treatment effectively reduced the levels of these biomarkers. Finally, abnormal levels of mtDNA were also found in plasma of HD patients relative to control subjects. Therefore, we identified several potential peripheral biomarkers as candidates to assess HD progression and the benefit of intervention for future clinical trials.
Dexamethasone Palmitate for Engraftment Syndrome Is Associated with Favorable Transplant Outcome for Children with Hematological Malignancy
Authors: Hirotoshi Sakaguchi, Kimikazu Matsumoto, Kotaro Narita, Motoharu Hamada, Shinsuke Kataoka, Naoyuki Miyagawa, Nao Yoshida, Masafumi Ito, Koji Kato
Journal: Blood (2015)
The Intra-Bone Route of Administration of Cord blood cells extends the Possibility of Transplantation to the Majority of Patients with Malignant Hematopoietic Diseases.
Authors: Francesco Frassoni, Marina Podestà, Simona Pollichieni, Francesca Gualandi, GianLuca Ubezio, Lucia Garbarino, Teresa Lamparelli, Riccardo Varaldo, Gianmario Sambuceti, Myriam Labopin, Andrea Bacigalupo, Nicoletta Sacchi
Journal: Blood (2009)
Prognostic Significance of WT1 mRNA and Anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes.
Authors: Hideto Tamura, Kazuo Dan, Norio Yokose, Rika Iwakiri, Masatsugu Ohta, Hisashi Sakamaki, Kaoru Tohyama, Kondo Asaka, Hideya Hyodo, Kyoko Nakamura, Taishi Yamashita, Olga A Elisseeva, Yoshihiro Oka, Yusuke Oji, Haruo Sugiyama, Kiyoyuki Ogata
Journal: Blood (2009)
A Gene Expression Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma.
Authors: Dirk Hose, Thierry Rème, Thomas Hielscher, Jérôme Moreaux, Tobias Meißner, Anja Seckinger, Axel Benner, Michael Hundemer, John Shaughnessy, Bart Barlogie, Jens Hillengass, Uta Bertsch, Anna Jauch, Jean François Rossi, Thomas Möhler, Bernard Klein, Hartmut Goldschmidt
Journal: Blood (2008)
Continuous Decline in Second Malignancy Occurrence in Patients with Hodgkin Lymphoma; Analysis of 1670 Patients Over the Past 5 Decades
Authors: Bouthaina S. Dabaja, Ferial Shihadeh, Carol Etzel, Liang Fu-wen, Shervin Mohajer Shirvani, Leslie Ballas, Pamela Allen, Maria A. Rodriguez, Michelle A. Fanale, Anas Younes
Journal: Blood (2011)
The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells.
Authors: Douglas Ivancsits, Rama Nimmanapali, Megan Sun, Kevin Shenk, Susan D. Demo, Mark K. Bennett, William S. Dalton, Melissa Alsina
Journal: Blood (2005)
Attempt to Discontinue Imatinib Following Interferon Alfa Pre-Treatment In Chronic Phase CML Patients Achieving Stable Complete Cytogentic Responses (CCyR)
Authors: Izhar Hardan, Yulia Volchek, Tali Tohami, Ninette Amariglio, Luba Trakhtenbrot, Maya Koren-Michowitz, Arnon Nagler
Journal: Blood (2010)
Comparison of IV Busulfan and Fludarabine Vs Oral Busulfan Plus Cyclophosphamide As Myeloablative Conditioning Regimens for Acute Leukemias and Myelodisplastic Syndromes
Authors: Gregorio Jaimovich, Alejandro Requejo, Vera Milovic, Nicolas Fernandez Escobar, Guillermo Drelichman, Juan Real, Sandra Brioschi, Leonardo Julio Feldman
Journal: Blood (2011)
Photodynamic Therapy (PDT)-Mediated Inhibition of the Transcription Factor Yin Yang 1 (YY1) That Regulates Resistance In Lymphoma
Authors: Valentina Rapozzi, Sara Huerta-Yepez, Abhijeet Joshi, Mario I. Vega, Stavroula Baritaki, Luigi E. Xodo, Benjamin Bonavida
Journal: Blood (2010)